Coagulation is initiated by the binding of factor Vlla t o tissue factor, with resultant limited factor IX and X activation and thrombin production. Owing t o the feedback inhibition of the factor Vllaltissue factor complex by tissue factor pathway inhibitor (TFPI), additional factor X activation and thrombin generation must proceed through a pathway involving factors VIII, IX, and XI. Experiments designed t o elucidate the requirement for amplified factor Xa and thrombin generation in normal hemostasis show that the resistance of plasma clots t o tissue plasminogen activator (tPA)-and urokinase-induced fibrinolysis is related t o the extent of thrombin generation. Inhibition of fibrinolysis is mediated in part by plasma carboxypeptidase-U ([CPU] carboxypeptidase-R, procarboxypeptidase-B, thrombin-activatable fibrinolysis inhibitor), a proenzyme that is proteolytically activated by thrombin in a process enhanced dramatically by the cofactor thrombomodulin. A clot induced in factor IXdeficient plasma with limited amounts of tissue factor in the N THE CURRENT SCHEME' for the process of coagula-I tion, the process is initiated when tissue factor is exposed at a site of blood vessel injury. Factors VI1 and VIIa in plasma bind to this tissue factor, and the factor VIIdtissue factor catalytic complex activates limited quantities of factor X and factor IX. Some of the factor Xa goes on to generate thrombin, which produces local activation of platelets and factors V, VIII, and XI11 and potentially initial fibrin formation. Tissue factor pathway inhibitor (TFPI) dampens the clotting process by directly binding and inhibiting some of the factor Xa that is generated and producing feedback inhibition of the factor VIIdtissue factor complex. Persistent and amplified production of factor Xa and thrombin then proceeds through the actions of factor IXa with its cofactor VIIIa. Factor XIa, possibly activated by or by other means, produces additional factor IXa to supplement that initially generated by the factor VIIdtissue factor complex before its inactivation by TFPI.
I tion, the process is initiated when tissue factor is exposed at a site of blood vessel injury. Factors VI1 and VIIa in plasma bind to this tissue factor, and the factor VIIdtissue factor catalytic complex activates limited quantities of factor X and factor IX. Some of the factor Xa goes on to generate thrombin, which produces local activation of platelets and factors V, VIII, and XI11 and potentially initial fibrin formation. Tissue factor pathway inhibitor (TFPI) dampens the clotting process by directly binding and inhibiting some of the factor Xa that is generated and producing feedback inhibition of the factor VIIdtissue factor complex. Persistent and amplified production of factor Xa and thrombin then proceeds through the actions of factor IXa with its cofactor VIIIa. Factor XIa, possibly activated by or by other means, produces additional factor IXa to supplement that initially generated by the factor VIIdtissue factor complex before its inactivation by TFPI.
Previous studies have shown that when coagulation is initiated by low concentrations of tissue factor, the quantities of factor Xa4 and thrombin5 generated in hemophilic plasma are markedly lower than the levels generated in normal plasma. That the amplified generation of factor Xa and thrombin produced through the actions of factors VI11 and IX, and in certain circumstances, factor XI, are necessary for ultimate hemostasis is attested to by the hemorrhagic diatheses associated with deficiencies in these factors. However, low concentrations of thrombin ( < 2 U/mL) are sufficient to activate platelets, factor XIII, and the critical cofactors V and VI11 and to clot fibrinogen in plasma. Clearly, the rapid production of significant quantities of thrombin is necessary to overcome the effects of plasma protease inhibitors, but in plasma systems in vitro, most of the prothrombin activation occurs after initial fibrin This implies that one role of the amplified thrombin generation produced through the actions of factors VIII, IX, and XI is to consolidate and sustain the fibrin clot.
presence of urokinase (100 U/mL) lyses prematurely, and this defect is corrected by supplementation of the deficient plasma with factor IX (5 pg/mL) or thrombomodulin (20 n g l mL). These additions enhance the rate and extent of CPU activation: in the case of factor IX, presumably by permitting amplified generation of factor Xa and thrombin, and in the case of thrombomodulin, presumably by increasing the degree of CPU activation produced by the low levels of thrombin generated in the absence of factor IX. Pretreatment of the factor IX-deficient plasma with specific anti-CPU antibodies prevents the increased resistance t o fibrinolysis produced by addition of factor IX and thrombomodulin. Likewise, when coagulation is induced by thrombin (2 UlmL) in the presence of tPA (60 UlmL), clots formed from plasmas deficient in factors VIII, IX, X, or XI lyse prematurely unless the missing factor is replaced or thrombomodulin (20 ng/ mL) is added. 0 1996 b y The American Society of Hematology.
At the site of a wound, there is a dynamic interplay between the coagulation and fibrinolysis pathways. Procoagulant forces must first produce and maintain the fibrin clot to prevent hemorrhage and permit reparative processes to function. However, fibrinolysis, as well as other proteolytic pathways, must ultimately break down the clot to facilitate wound healing and tissue remodeling. The bleeding in hemophilia may in part represent an imbalance in this coagulationfibrinolysis dichotomy in which the lack of amplified and persistent factor Xa production and resultant thrombin generation permits premature lysis of the clot. Such a scenario is consistent with the bleeding in hemophiliacs that frequently follows an injury by hours to days and can be particularly troublesome in areas with high endogenous fibrinolytic activity such as the oral In a series of experiments examining whether the extent of factor Xa and thrombin generation during coagulation affects the subsequent fibrinolytic process, plasma carboxypeptidase-U (CPU) was identified as a critical component in coagulation-mediated resistance to fibrinolysis. CPU was initially identified by Hendriks et al"'" as having a carboxypeptidase-B -like activity, separate from carboxy-3816 kDa BROZE AND HlGUCHl of CPU may in part explain the requirement for factors VIII. IX, and XI for sustained hemostasis.
MATERIALS AND METHODS
Sodium dodecyl sulfate (SDS). Trizma base. HEPES, EDTA. diisopropylfluorophosphate (DFP). Tween 20. Q Fast-Flow. phenylSepharose. heparin-agarose, arginine-agarose. c-aminocaproic acid (EACA). rabbit brain cephalin, and aprotinin were purchased from Sigma Chemical Co (St Louis, MO). The plasmin chromogenic substrate S239O was from Chromogenix (Franklin, OH). and the specific carboxypeptidase-B inhibitor DL-2-mercaptomethyl-3-guanidinethyl-thiopropanoic acid (MERGETPA) and the thrombin inhibitor H-D-phenylalanyl-L-propyl-arginine chloromethyl ketone (PPACK) were from Calbiochem (La Jolla. CA). Affigel-I0 was purchased from Bio-Rad Laboratories (Hercules. CA).
Barium-absorbed plasma (BAP) was produced from fresh venopuncture blood drawn into 100 mmol/L sodium oxalate (9: I vol/vol). Following removal of cellular elements by centrifugation (4.000,q for 10 minutes at room temperature). the plasma was absorbed twice with barium sulfate (100 mg/mL at 4°C). dialyzed extensively against 0.15 mol/L NaCI/O.OI mol/L HEPES (HBS). pH 7.4, at 4°C. and stored in small aliquots at -7OOC. To produce EDTA/ BAP. BAP was treated with 0.1 mmol/L EDTA for 30 minutes at 37°C and then dialyzed extensively against HBS at 4°C before storage in aliquots at -70°C.
Pooled normal human plasma and plasmas deficient in factors VIII. IX. X, XI. and XI1 were obtained from George King Biomedical (Overland Park, KS).
Prothrombin, factor X, and factor IX were purified from fresh frozen plasma, and thrombin (3,500 Ulmg) was produced from purified prothrombin as previously described.'"."' Two-chain tissue plasminogen activator ([PA; 700,000 IUlmg) was obtained from American Diagnostica Inc (Greenwich, CT). Plasminogen was purified from human plasma using lysine-Sepharose" and linked to Affigel-IO at a concentration of 5 mg/mL settled gel by the manufacturer's method. CPN was purified using the method of Hendriks et al." Urokinase was the therapeutic product. Abbokinase, from Abbott Laboratories (Chicago, IL). Following reconstitution of the lyophilized product with water. each milliliter contains 50. OOO IU urokinase, 0.59 mannitol. 5% human albumin. and 1% sodium chloride. The factor VI11 source was Monoclate-P (Armour, Collegeville, PA). Tissue factor was a crude preparation of human brain thromboplastin that had been washed extensively with EDTA.'' A 75-kD partially glycosylated form of soluble human thrombomodulin that lacks the transmembrane and cytoplasmic domains of the native molecule was a kind gift from John Parkinson (Berkx Biosciences, Richmond. CA)." CPU activity was followed during the purification procedure using a qualitative assay for thrombin-dependent inhibition of fibrinolysis (see below). Fresh blood ( I U) was drawn by venipuncture into sodium oxalate ( I 0 0 mmollL. 9:l vollvol) and centrifuged at room temperature (4,0008 for 10 minutes) to remove the blood cells. Aprotinin (10 KIU/mL) and DFP ( 1 mmol/L) were added to the supernatant plasma, and it was stirred with barium sulfate (100 mglmL) at 4°C for 30 minutes. Following centrifugation (I0.000g for 30 minutes at 4°C). ammonium sulfate (30% saturation) was added to the absorbed plasma, and the mixture was stirred for 60 minutes at 4°C: After centrifugation (l0.OOOg for 30 minutes at 4°C). the supernatant was dialyzed extensively against 0.01 mol/L HEPES, pH 7.4. at 4°C. The preparation was then applied at room temperature to a 2.5 x 55-cm column of Q Fast-Flow equilibrated in 0.01 mol/L HEPES. pH 7.4. and the column was developed with a 1.6-L gradient from 0 to 0.5 mol/L NaCI. Fractions containing Plasmns.
Profeins.
Isolnfiori of Cf U. peptidase-N (CPN), that was produced during the coagulation of plasma. Its instability in serum at 37°C led to the designation carboxypeptidase-U (unstable). Shortly thereafter, Campbell et al"." confirmed these studies and referred to the enzyme as carboxypeptidase-R, since it appeared to prefer arginine over lysine residues at the carboxy terminus of substrates. In 1991, Eaton et al" isolated a carboxypeptidase proenzyme from plasma based on its ability to bind to a plasminogen affinity column, and called it procarboxypeptidase-B. They noted that the purified carboxypeptidase was proteolytically cleaved by trypsin, thrombin, and plasmin with the apparent release of an amino-terminal activation peptide, and that the activated enzyme was unstable. Later, Wang et all' reported that the carboxypeptidase isolated by Eaton et al and the previously identified CPU were the same, and that the enzyme was present in preparations of plasminogen isolated by lysine-Sepharose affinity chromatography.
-
As the current study was in progress, Bajzar et all5 reported that CPU is a thrombin-activatable inhibitor of fibrinolysis and renamed the molecule TAFI. Their investigation was prompted by their previous studies showing that the enhanced fibrinolysis produced by activated protein C was related to its reduction in ultimate thrombin generation," and by the observation that this thrombin-mediated inhibition of fibrinolysis required a component that was a contaminant in preparations of purified plasminogen.'".'' In a recent preliminary report, Bajzar and Nesheim" have shown that thrombomodulin enhances thrombin activation of CPU greater than 1,000-fold. Here, we show that thrombin-dependent inhibition of fibrinolysis mediated through the action CPU activity, which eluted between the transferrin and albumin peaks (-0.12 molL NaCI), were pooled and applied to a heparinSepharose column (50 mL) equilibrated in 0.1 mom NaCVO.01 moVL HEPES, pH 7.4. After washing with equilibration buffer, the column was eluted with 1.0 mom NaCVO.01 mom HEPES, pH 7.4. Fractions containing CPU activity were pooled and applied to a 30" column of phenyl-Sepharose equilibrated in 1.0 mom NaCI/O.Ol molL HEPES, pH 7.4. After washing with equilibration buffer, the CPU was eluted with 0.01 m o m HEPES, pH 7.4. Pooled fractions following phenyl-Sepharose chromatography were applied to a plasminogen-agarose affinity column (4 mL) equilibrated in HBS at a flow rate of 8 mL/h. Following washing with equilibration buffer, the CPU was eluted with a 50-mL gradient from 0 to 0.05 molL EACA in HBS with 0.005% Tween 20. Fractions with activity were combined, the pool was concentrated (Amicon YM IO), and aliquots were stored at -70°C. By 12% SDS-PAGE, the isolated CPU appears more than 90% pure and is recognized on Westem blot by an antipeptide antibody raised against amino acid residues 156 to 168 of mature CPU" (Fig 1) . Before testing in fibrinolysis assays, EACA was removed from the CPU preparation by extensive dialysis. The CPU concentration was estimated by absorbance at 280 nm assuming E; : = 10. Purified CPU was radiolabeled with Iz1 to a specific activity of 5,000 d p d n g using Iodo-Beads (Pierce, Rockford, IL).
Immulon-2 flatbottom microtiter plates (Dynatech Laboratories Inc, Chantilly, VA), which do not support contact activationz3 or factor XI autoactivation (Gailani and Broze, unpublished observations, January 1993), are used for the assay. To a microtiter plate well are added 10 pL thrombin solution, 100 pL of a mixture containing rabbit brain cephalin, calcium chloride, and urokinase or tPA in 0.15 mom NaCV 0.01 m o m HEPES, pH 7.4, with 5 mg/mL bovine serum albumin, and the reaction is started with 100 pL plasma. Final concentrations of reactants are as follows: thrombin, 2 to 200 U/mL; rabbit brain cephalin, 2.5% (vollvol) of a stock prepared as described by the manufacturer (Sigma); urokinase or tPA, typically 60 to 125 IU/mL; and calcium chloride, 5 mmol/L for dialyzed BAP and EDTA/BAP, 12.5 m m o m for citrated plasma samples. In certain experiments, thrombin was omitted and coagulation initiated with tissue factor. Subsequent clot lysis was followed at A405 for 2 to 4 hours using Qualitative assay for inhibition of fibrinolysis.
For a Vmax microtiter plate reader from Molecular Devices (Menlo Park, CA). In some cases, results are presented as relative absorbance, where 1.0 is the peak A405 and 0 is the baseline A405 in the absence of induction of coagulation by thrombin or tissue factor.
To follow the activity of samples during purification of CPU, the assay was modified as follows: 10 pL thrombin (4 or 150 U/mL final) and 50 pL of a mixture of rabbit brain cephalin (2.5% VOV vol final), urokinase (100 IU/mL final), and calcium chloride (5 mmol/L final) were added to a microtiter well, and the reaction was started with 150 pL of a 2:l mixture of EDTA/BAP and the sample.
CPN activity was measured using the method of Schweisfurth et with minor modifications.
Other. SDS-PAGE and Western blotting were performed as previously described." Rabbit polyclonal antibodies against the synthetic peptide CGIHAREWISPAF and purified CPU were produced using standard techniques." To measure plasmin activity at the surface of a clot in a microtiter well, at specified times 50 pl, S2390 (2.0 mmol/L) is layered on top of the fibrin gel, and the rate of change in A405 is determined over IO minutes.
RESULTS
Coagulation-dependent inhibition ~$$brinolysi.s. To determine whether the extent of the coagulation process affects subsequent fibrinolysis, factor X-deficient plasma with or without supplementation with purified factor X was induced to clot in microtiter plates with thrombin (4 U/mL), tissue factor (1/1,000 vol/vol), phospholipids, and calcium ions in the presence of 100 IU/mL urokinase or tPA. Fibrinolysis was assessed by the reduction in turbidity (A405) of the plasma clots to a baseline value. Factor X-deficient plasma replenished with purified factor X is resistant to fibrinolysis over the 2-hour time course of the experiment, whereas factor X-deficient plasma lyses prematurely (not shown). To confirm a role for thrombin generation in the inhibition of fibrinolysis, fresh oxalated normal plasma was absorbed with barium sulfate to remove the vitamin K-dependent coagulation factors (including factors VII, IX, and X and prothrombin) and dialyzed into HBS. This BAP was then tested in the fibrinolysis assay using factor Xa (500 ng/mL) with varying concentrations of prothrombin to limit the extent of thrombin generation, or using varying concentrations of thrombin itself to induce coagulation. Increasing the concentrations of prothrombin or thrombin leads to progressive lengthening of fibrinolysis time (Fig 2) . The active catalytic site ofthrombin is important for thrombin-dependent inhibition of fibrinolysis, since addition of high levels of PPACK-inactivated thrombin (50 pg/mL) to clots formed with 4 U/mL active thrombin does not increase their resistance to fibrinolysis (not shown).
Preliminary studies showed that the thrombin-dependent inhibition of fibrinolysis is divalent cation-dependent. Pretreatment of BAP with EDTA (0.1 mmol/L) at 37°C for 30 minutes abrogates the antifibrinolytic effect of high thrombin concentrations even though calcium ions in excess of the EDTA chelation are provided within the fibrinolysis assay. To investigate the metal dependence of thrombin-dependent inhibition of tibrinolysis, BAP was treated with EDTA (0. l mmol/L for 30 minutes at 37°C) and dialyzed extensively against HBS. This EDTA-inactivated, dialyzed BAP (EDTNBAP) was then tested in the fibrinolysis assay following incubation with various metal ions at 37°C for 30 minutes. Regeneration of thrombin-dependent inhibition of fibrinolysis in the BAP occurs with nonphysiologic concentrations of cobalt and manganese ions ( 2 5 0 p m o l k ) and with physiologic concentrations of zinc ions (25 pmol/L) (Fig 3A) .
The time course of plasmin production in BAP, EDTA/ BAP, and EDTNBAP regenerated with zinc chloride (25 pmol/L) was assessed by overlaying the clots formed in the fibrinolysis assay at various times with a solution containing
Divalent cation dependence.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Minutes the plasmin chromogenic substrate S2390 (Fig 3B) . The generation of plasmin-mediated amidolytic activity at the clot surface is much slower in clots produced from BAP and EDTA/BAP regenerated with 25 pmollL zinc ions than in EDTAlBAP clots. Thus, thrombin-dependent inhibition of fibrinolysis appears to be due at least in part to the reduced generation of plasmin activity within the clot. For (Fig 7D) . The clot formed in reactions containing factor IX-deficient plasma alone lyses prematurely (Fig 7B) , and much of the apparent activation and degradation of "'I-CPU that occurs late in these reactions nlay be due to the action of plasmin (Fig 7A and B) .
In additional experiments. the fibrinolysis inhibition generated in several factor-deficient plasmas was tested using a simplified system in which thrombin (2 U/mL) rather than tissue factor is used to initiate coagulation. and tPA (60 U/ mL) instead of urokinase is used to initiate fibrinolysis. Un- '"I-CPU (2 pglmL1, thrombin (10 pglmL), phospholipids 11:40 of stock), calcium ions (4 mmollL1, and zinc ions (15 pmollL) was incubated at room temperature. At the specified times, a portion was removed and the reaction was terminated with an equal volume of 6 mol/L urea, 10% 2-mercaptoethanol, and 10% SDS, and heating at 100°C for 5 minutes. Samples (10 pL) were assayed on SDS-PAGE (15461, and the gel was dried before autoradiography. 
B C
to EDTA/BAP reestablishes thrombin-dependent inhibition of fibrinolysis (Fig 4) .
Factor IX-deficient plasma induced to clot with low levels of tissue factor ( 1 :20.000 vol/vol) in the presence of urokinase ( I00 U/mL) lyses prematurely. Factor IX-deficient plasma supplemented with factor IX (5 pg/mL), thrombomodulin (20 ng/mL), or EACA ( I .0 mmol/L), on the other hand, is resistant to fibrinolysis under the same conditions (Fig SA) . The inclusion Fihririolysis in fnctor-deficierif plcisrnn.
of rabbit polyclonal anti-CPU IgG. but not preimmune rabbit D IgG (not shown), in the mixtures hastens the lysis of clots induced in factor IX-deficient plasma by low levels of tissue factor and abrogates the resistance to fibrinolysis produced by the addition of factor IX and thrombomodulin (Fig SB) .
In similar reactions, radiolabeled CPU was added to the factor IX-deficient plasma, and the time course of '251-CPU cleavage was examined by SDS-PAGE and autoradiography. Proteolytic activation of CPU by thrombin or plasmin involves the removal of the amino-terminal portion of the zymogen with the production of a 35.000-MW activated form (CPUa) (Fig 6) ."." However, alternative cleavage at a site within the carboxy-terminal domain of CPU and CPUa leads to degradation products of 53,000 and 25.000 MW.
respectively. Addition of factor IX (5 pg/mL) to factor IXdeficient plasma leads to earlier, presumably thrombin-mediated '251-CPU activation (Fig 7B v C) . Supplementation of factor IX-deficient plasma with thrombomodulin (20 ng/ mL) produces more rapid and more extensive "'I-CPU acti- Activation of '251-CPU in factor IX-deficient plasma. Mixtures (50 pL1 containing 'z51-CPU 12 pglmL) and factor IX-deficient plasma, phospholipids, tissue factor, calcium ions with or without added urokinase, factor IX, and thrombomodulin at the same concentrations as in Fig 5 were made at room temperature in Eppendorf tubes. At the specified times, the reactions were terminated with an equal volume of 6 mollL urea, 10% 2-mercaptoethanol, and 10% SDS, and heating at 90°C for 15 minutes. Samples (10 pL) were assayed on SDS-PAGE 112.5%). and the gel was dried before autoradiography. der these conditions, the premature lysis of clots from factor X-, IX-, VIII-, and XI-deficient plasmas is also corrected by addition of the missing coagulation factor or addition of thrombomodulin (20 ng/mL), in part confirming the previous results of other^^',^^ (Fig 8) . Interestingly, the fibrinolysis resistance of the clot formed with factor XII-deficient plasma in Fig 8 and two additional commercially available factor XII-deficient plasmas (not shown) approaches that of normal plasma.
DISCUSSION
CPU was discovered several years ago as a carboxypeptidase-B -like activity that appeared following the coagulation of p l a~m a ,~. '~ but it was not until the report by Bajzar et alls that a potential physiologic function of CPU was identified. Prompted by their observation that the apparent profibrinolytic effect of activated protein C was related to its reduction in thrombin generation,I6 the researchers identified CPU as a thrombin-activatable inhibitor of fibrinolysis (TAFI). The experiments reported here, initiated in an attempt to understand the hemostatic requirement for the amplified and sustained generation of factor Xa and thrombin produced through the actions of factors VIII, IX, and XI, also support a role for CPU in coagulation-dependent inhibition of fibrinolysis. Interestingly, thrombomodulin serves as a cofactor for thrombin activation of both protein C34 and CPU." In the in vitro plasma fibrinolysis system used here, the effect of soluble thrombomodulin on the activation of CPU appears to be predominant. Whether the same is true for cell-associated thrombomodulin or whether other plasma cofactors may modulate the extent or timing of protein C and CPU activation by thrombidthrombomodulin is not known.
CPU-dependent inhibition of fibrinolysis is associated with a decrease in the generation of plasmin activity within the fibrin clot (Fig 3) . Previous studies have shown that
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 3822 BROZE AND HIGUCHI limited plasmin degradation of fibrin produces polypeptides with carboxy-terminal basic residues, thereby increasing plasminogen binding and the rate of plasminogen activation by both urokinase and tPA.27-29 Treatment with pancreatic carboxypeptidase-B abrogates this feedback enhancement of fibrinolysis by removing the carboxy-terminal basic residues from the fibrin polypeptides produced by plasmin.29 Whether the action of CPUa involves a similar mechanism, as recently suggested by Redlitz et a1," andlor is mediated by other antifibrinolytic effects of CPU is not known. Furthermore, the coagulation process may affect subsequent fibrinolysis through means unrelated to CPU.
The in vitro fibrinolysis assay appears to demonstrate an important abnormality of clots produced with hemophilic plasma that may be related to the delayed bleeding seen in individuals with hemophilia, particularly from wounds at sites with high intrinsic fibrinolytic activity. When limiting concentrations of tissue factor are used to initiate coagulation in factor IX-deficient plasma in the presence of a plasminogen activator, the subsequent clot lyses prematurely. This defect can be reversed by supplementation of the deficient plasma with factor IX or by addition of thrombomodulin (Fig 5) . Other manipulations, such as depleting the plasma of TFPI, adding factor VIIa (5 pg/mL), or increasing the concentration of tissue factor used to initiate coagulation,'"'* also prolong the lysis time of clots formed with factor IX plasma (Broze and Higuchi, unpublished data, May 1995). Most of these interventions lead to increased factor Xa and thrombin production. However, thrombomodulin presumably does not enhance the tissue factor-mediated generation of factor Xa and thrombin in factor IX-deficient plasma, but may instead increase the activation of CPU by the low concentrations of thrombin formed under these conditions."
